8-K: Indivior Appoints Joe Ciaffoni as CEO, Announces Board Changes in Agreement with Oaktree

Indivior PLC announces the appointment of Joe Ciaffoni as CEO, along with several board changes and an amended agreement with Oaktree Capital Management.

Summary

• Indivior PLC has appointed Joe Ciaffoni as Chief Executive Officer, effective after the 2025 AGM but no later than August 1, 2025, subject to shareholder approval of a new remuneration policy.
• Mark Crossley will remain as CEO until at least the date of the 2025 AGM to support the transition.
• Ciaffoni's employment agreement includes an annual base salary of $1,050,000 and a target annual cash bonus of 100% of his base salary, with a maximum of 200%.
• He will receive long-term incentive awards starting in 2026, with grant-date values ranging from 400% to at least 700% of his base salary.
• In lieu of a 2025 long-term incentive award, Ciaffoni will receive performance stock units (PSUs) with a grant-date value of 12 times his base salary, capped at 1.575 million shares, and restricted stock units (RSUs) with a grant-date value of four times his base salary, capped at 525,000 shares.
• Indivior has amended its Relationship Agreement with Oaktree Capital Partners, agreeing to appoint Joe Ciaffoni and Daniel Ninivaggi to the board of directors.
• Daniel Ninivaggi will become Chair of the Nomination Committee.
• The company will propose a maximum of seven directors for re-election at the 2025 AGM, including Ciaffoni and Ninivaggi.
• Following the 2025 AGM, Indivior will search for and appoint one additional external candidate to become a Non-Executive Director, subject to Oaktree's approval.
• The maximum number of directors following the 2025 AGM until the expiry of the Relationship Agreement will be eight.
• Robert Schriesheim resigned from the Board on March 2, 2025.
• Peter Bains and Jo LeCouilliard will not stand for re-election at the Company's Annual General Meeting.
• The Relationship Agreement will terminate on December 31, 2025, but Oaktree can terminate it earlier if Indivior breaches certain provisions.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and neutral information. The appointment of a new CEO and board changes are generally positive, but the transition period and potential risks associated with the Relationship Agreement with Oaktree temper the overall sentiment.

Positives

• The appointment of a new CEO, Joe Ciaffoni, could bring fresh leadership and strategic direction to Indivior.
• The amended Relationship Agreement with Oaktree provides clarity and structure to the relationship between the company and a major shareholder.
• The board changes, including the appointment of Daniel Ninivaggi as Chair of the Nomination Committee, may improve corporate governance.
• The reduction in board size to seven directors could lead to more efficient decision-making.
• The long-term incentive plan for the new CEO aligns his interests with those of the shareholders.

Negatives

• The transition period with Mark Crossley remaining as CEO until the 2025 AGM could create uncertainty.
• The reliance on shareholder approval for the new remuneration policy introduces a potential risk if the policy is not approved.
• The Relationship Agreement with Oaktree includes restrictions on the company's actions, which could limit its flexibility.
• The departure of Robert Schriesheim, Peter Bains, and Jo LeCouilliard from the board could result in a loss of experience and expertise.

Risks

• Failure to obtain shareholder approval for the new remuneration policy could impact the terms of Joe Ciaffoni's employment agreement.
• The Relationship Agreement with Oaktree could limit the company's ability to make strategic decisions independently.
• The search for a new independent Non-Executive Director could be delayed or unsuccessful.
• The transition to a new CEO could be disruptive to the company's operations.
• The company's performance may not meet the targets required for Joe Ciaffoni to achieve his maximum bonus potential.

Future Outlook

The company anticipates a smooth transition to the new CEO and aims to strengthen its board with the addition of a new independent director. The company will continue to focus on developing medicines to treat substance use disorders.

Management Comments

• Dr David Wheadon, Chair said, Peter Bains, Jo LeCouilliard and Rob Schriesheim have been unswerving in their support of bringing needed therapeutic interventions to patients suffering from Opioid Use Disorder.
• Dr Wheadon stated that he sincerely thanks them for the service they have given to Indivior.

Industry Context

In the pharmaceutical industry, leadership changes and board restructuring are common events, often driven by strategic shifts, mergers, or shareholder activism. Indivior's focus on substance use disorders aligns with growing public health concerns and increasing investment in this area.

Comparison to Industry Standards

• CEO compensation packages in the pharmaceutical industry typically include a base salary, annual bonus, and long-term incentives such as stock options or restricted stock units.
• The base salary of $1,050,000 for Indivior's new CEO is within the range of salaries for CEOs of similar-sized pharmaceutical companies.
• The long-term incentive awards, ranging from 400% to 700% of the base salary, are also consistent with industry standards.
• Companies like Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris) have undergone similar leadership transitions and board restructuring in recent years.
• The involvement of Oaktree Capital Partners in Indivior's board changes is similar to activist investors influencing corporate governance at other pharmaceutical companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a new CEO and board changes could impact the company's stock price and overall performance.
• Employees: The transition to a new CEO could create uncertainty among employees.
• Customers: The company's focus on developing medicines to treat substance use disorders could benefit patients.
• Suppliers: The company's financial performance could impact its relationships with suppliers.
• Creditors: The company's financial stability could impact its ability to meet its obligations to creditors.

Next Steps

• Shareholder approval of the new remuneration policy at the 2025 AGM.
• Commencement of Joe Ciaffoni's service as CEO after the 2025 AGM but no later than August 1, 2025.
• Search for and appointment of one additional external candidate to become a Non-Executive Director, subject to Oaktree's approval.
• Implementation of the board changes, including the appointment of Daniel Ninivaggi as Chair of the Nomination Committee and Barbara Ryan as Chair of the Compensation Committee.

Key Dates